Clemen­tia keeps the biotech IPO par­ty go­ing with $120M play on an up­sized of­fer­ing

David Mott, the pro­lif­ic New En­ter­prise As­so­ciates gen­er­al part­ner, has an­oth­er suc­cess­ful IPO un­der his belt for an­oth­er one of his port­fo­lio com­pa­nies.

Que­bec-based Clemen­tia …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER